{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T10:33:46Z","timestamp":1783420426891,"version":"3.54.6"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,9,16]],"date-time":"2015-09-16T00:00:00Z","timestamp":1442361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2015,9,16]],"date-time":"2015-09-16T00:00:00Z","timestamp":1442361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s10637-015-0286-7","type":"journal-article","created":{"date-parts":[[2015,9,16]],"date-time":"2015-09-16T07:52:56Z","timestamp":1442389976000},"page":"1206-1216","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors"],"prefix":"10.1007","volume":"33","author":[{"given":"Sandrine J.","family":"Faivre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Olszanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Weigang-K\u00f6hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanno","family":"Riess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger B.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott P.","family":"Myrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enaksha R.","family":"Wickremsinhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candice L.","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojun","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Callies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim A.","family":"Benhadji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Raymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,16]]},"reference":[{"key":"286_CR1","unstructured":"Gemzar Summary of Product Characteristics (SPC) http:\/\/agence-prd.ansm.sante.fr\/html\/par_eu\/20110907_fr390_gemcitabinemylan_spc.pdf. Accessed 24 November 2014"},{"key":"286_CR2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.1991.9.3.491","volume":"9","author":"JL Abbruzzese","year":"1991","unstructured":"Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN (1991) A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491\u2013498","journal-title":"J Clin Oncol"},{"key":"286_CR3","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1200\/JCO.2001.19.15.3483","volume":"19","author":"SR Patel","year":"2001","unstructured":"Patel SR, Gandhi V, Jenkins J, Papadopolous N, Burgess MA, Plager C, Plunkett W, Benjamin RS (2001) Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 19:3483\u20133489","journal-title":"J Clin Oncol"},{"key":"286_CR4","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1200\/JCO.2003.09.140","volume":"21","author":"M Tempero","year":"2003","unstructured":"Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402\u20133408","journal-title":"J Clin Oncol"},{"key":"286_CR5","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s00535-005-1724-7","volume":"41","author":"H Sakamoto","year":"2006","unstructured":"Sakamoto H, Kitano M, Suetomi Y, Takeyama Y, Ohyanagi H, Nakai T, Yasuda C, Kudo M (2006) Comparison of standard-dose and low-dose gemcitabine regimens in pancreatic adenocarcinoma patients: a prospective randomized trial. J Gastroenterol 41:70\u201376","journal-title":"J Gastroenterol"},{"key":"286_CR6","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/01.mpa.0000153335.73352.c7","volume":"30","author":"Y Takahashi","year":"2005","unstructured":"Takahashi Y, Mai M, Sawabu N, Nishioka K (2005) A pilot study of individualized maximum repeatable dose (iMRD), a new dose finding system, of weekly gemcitabine for patients with metastatic pancreas cancer. Pancreas 30:206\u2013210","journal-title":"Pancreas"},{"key":"286_CR7","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1158\/1535-7163.MCT-12-0654","volume":"12","author":"SE Pratt","year":"2013","unstructured":"Pratt SE, Durland-Busbice S, Shepard RL, Donoho GP, Starling JJ, Wickremsinhe ER, Perkins EJ, Dantzig AH (2013) Efficacy of low-dose oral metronomic dosing of the prodrug of gemcitabine, LY2334737, in human tumor xenografts. Mol Cancer Ther 12:481\u2013490","journal-title":"Mol Cancer Ther"},{"key":"286_CR8","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1158\/1078-0432.CCR-07-4521","volume":"14","author":"SA Veltkamp","year":"2008","unstructured":"Veltkamp SA, Jansen RS, Callies S, Pluim D, Visseren-Grul CM, Rosing H, Kloeker-Rhoades S, Andre VA, Beijnen JH, Slapak CA, Schellens JH (2008) Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study. Clin Cancer Res 14:3477\u20133486","journal-title":"Clin Cancer Res"},{"key":"286_CR9","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0090-9556(25)08805-1","volume":"20","author":"LA Shipley","year":"1992","unstructured":"Shipley LA, Brown TJ, Cornpropst JD, Hamilton M, Daniels WD, Culp HW (1992) Metabolism and disposition of gemcitabine, and oncolytic deoxycytidine analog, in mice, rats, and dogs. Drug Metab Dispos 20:849\u2013855","journal-title":"Drug Metab Dispos"},{"key":"286_CR10","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1021\/mp300370t","volume":"10","author":"E Moysan","year":"2013","unstructured":"Moysan E, Bastiat G, Benoit JP (2013) Gemcitabine versus modified gemcitabine: a review of several promising chemical modifications. Mol Pharm 10:430\u2013444","journal-title":"Mol Pharm"},{"key":"286_CR11","doi-asserted-by":"publisher","first-page":"6958","DOI":"10.1021\/jm901181h","volume":"52","author":"DM Bender","year":"2009","unstructured":"Bender DM, Bao J, Dantzig AH, Diseroad WD, Law KL, Magnus NA, Peterson JA, Perkins EJ, Pu YJ, Reutzel-Edens SM, Remick DM, Starling JJ, Stephenson GA, Vaid RK, Zhang D, McCarthy JR (2009) Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine. J Med Chem 52:6958\u20136961","journal-title":"J Med Chem"},{"key":"286_CR12","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1158\/1078-0432.CCR-12-1184","volume":"19","author":"SE Pratt","year":"2013","unstructured":"Pratt SE, Durland-Busbice S, Shepard RL, Heinz-Taheny K, Iversen PW, Dantzig AH (2013) Human carboxylesterase 2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cells. Clin Cancer Res 19:1159\u20131168","journal-title":"Clin Cancer Res"},{"key":"286_CR13","doi-asserted-by":"publisher","first-page":"6071","DOI":"10.1158\/1078-0432.CCR-11-0353","volume":"17","author":"SL Koolen","year":"2011","unstructured":"Koolen SL, Witteveen PO, Jansen RS, Langenberg MH, Kronemeijer RH, Nol A, Garcia-Ribas I, Callies S, Benhadji KA, Slapak CA, Beijnen JH, Voest EE, Schellens JH (2011) Phase I study of oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors. Clin Cancer Res 17:6071\u20136082","journal-title":"Clin Cancer Res"},{"key":"286_CR14","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1007\/s00280-013-2165-2","volume":"71","author":"N Yamamoto","year":"2013","unstructured":"Yamamoto N, Nokihara H, Yamada Y, Uenaka K, Sekiguchi R, Makiuchi T, Slapak CA, Benhadji KA, Tamura T (2013) Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 71:1645\u20131655","journal-title":"Cancer Chemother Pharmacol"},{"key":"286_CR15","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"286_CR16","doi-asserted-by":"publisher","first-page":"6576","DOI":"10.1021\/ac100984h","volume":"82","author":"ER Wickremsinhe","year":"2010","unstructured":"Wickremsinhe ER, Lutzke BS, Jones BR, Schultz GA, Freeman AB, Pratt SE, Bones AM, Ackermann BL (2010) Quantification of gemcitabine incorporation into human DNA by LC\/MS\/MS as a surrogate measure for target engagement. Anal Chem 82:6576\u20136583","journal-title":"Anal Chem"},{"issue":"Suppl 2","key":"286_CR17","doi-asserted-by":"publisher","first-page":"S359","DOI":"10.1016\/S0753-3322(05)80078-2","volume":"59","author":"T Ueno","year":"2005","unstructured":"Ueno T, Toi M, Linder S (2005) Detection of epithelial cell death in the body by cytokeratin 18 measurement. Biomed Pharmacother 59(Suppl 2):S359\u2013S362","journal-title":"Biomed Pharmacother"},{"key":"286_CR18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ejca.2010.08.006","volume":"47","author":"L De Petris","year":"2011","unstructured":"De Petris L, Brand\u00e9n E, Herrmann R, Sanchez BC, Koyi H, Linderholm B, Lewensohn R, Linder S, Lehti\u00f6 J (2011) Diagnostic and prognostic role of plasma levels of two forms of cytokeratin 18 in patients with non-small-cell lung cancer. Eur J Cancer 47:131\u2013137","journal-title":"Eur J Cancer"},{"key":"286_CR19","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1586\/erm.10.14","volume":"10","author":"S Linder","year":"2010","unstructured":"Linder S, Olofsson MH, Herrmann R, Ulukaya E (2010) Utilization of cytokeratin-based biomarkers for pharmacodynamic studies. Expert Rev Mol Diagn 10:353\u2013359","journal-title":"Expert Rev Mol Diagn"},{"key":"286_CR20","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.2307\/2533494","volume":"53","author":"PD Sasieni","year":"1997","unstructured":"Sasieni PD (1997) From genotypes to genes: doubling the sample size. Biometrics 53:1253\u20131261","journal-title":"Biometrics"},{"key":"286_CR21","doi-asserted-by":"publisher","first-page":"e1001046","DOI":"10.1371\/journal.pbio.1001046","volume":"9","author":"ENCODE Project Consortium","year":"2011","unstructured":"ENCODE Project Consortium (2011) A user\u2019s guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol 9:e1001046. doi:10.1371\/journal.pbio.1001046","journal-title":"PLoS Biol"},{"key":"286_CR22","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s00280-014-2457-1","volume":"73","author":"R Salazar","year":"2014","unstructured":"Salazar R, Morales S, Gil-Mart\u00edn M, Aguirre E, Oaknin A, Garcia M, Callies S, Wickremsinhe ER, Benhadji KA, Llombart A (2014) Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 73:1205\u20131215","journal-title":"Cancer Chemother Pharmacol"},{"key":"286_CR23","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s10637-015-0207-9","volume":"33","author":"JR Infante","year":"2015","unstructured":"Infante JR, Benhadji KA, Dy G, Fetterly G, Wee Ma W, Callies S, Adjei AA (2015) Phase 1 study of oral gemcitabine prodrug LY2334737 in combination with capecitabine in patients with advanced solid tumors. Investig New Drugs 33:432\u2013439","journal-title":"Investig New Drugs"},{"key":"286_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.gene.2013.04.015","volume":"524","author":"SN Iyer","year":"2013","unstructured":"Iyer SN, Ankala A, Singhal RS, Hegde MR (2013) Determination of common genetic variants in cytidine deaminase (CDA) gene in Indian ethnic population. Gene 524:35\u201339","journal-title":"Gene"},{"key":"286_CR25","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1200\/JCO.2006.06.7405","volume":"25","author":"E Sugiyama","year":"2007","unstructured":"Sugiyama E, Kaniwa N, Kim SR, Kikura-Hanajiri R, Hasegawa R, Maekawa K, Saito Y, Ozawa S, Sawada J, Kamatani N, Furuse J, Ishii H, Yoshida T, Ueno H, Okusaka T, Saijo N (2007) Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J Clin Oncol 25:32\u201342","journal-title":"J Clin Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-015-0286-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-015-0286-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-015-0286-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-015-0286-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T17:36:44Z","timestamp":1748626604000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-015-0286-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,16]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["286"],"URL":"https:\/\/doi.org\/10.1007\/s10637-015-0286-7","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,16]]},"assertion":[{"value":"21 May 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}